| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/28/2011 | CN102198150A Antitumor drug with double active components and application thereof |
| 09/28/2011 | CN101318020B Anti-anxiety or/and dumps medicament composition and uses thereof |
| 09/28/2011 | CN101039695B Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes |
| 09/27/2011 | US8026371 Hydroxamates as therapeutic agents |
| 09/27/2011 | US8026238 Topical antifungal composition |
| 09/27/2011 | US8026213 Methods for treating muscle diseases and disorders |
| 09/27/2011 | US8026210 Exendins and exendin agonist analogs to regulate gastrointestinal motility |
| 09/27/2011 | US8026109 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/27/2011 | US8025898 Enhanced drug delivery in transdermal systems |
| 09/27/2011 | US8025890 Nucleic acids and proteins from streptococcus groups A and B |
| 09/27/2011 | US8025883 Antagonists and methods for inhibiting angiogenesis |
| 09/27/2011 | CA2473409C Phenoxy-piperidines for the treatment of diseases such as schizophrenia and depression |
| 09/27/2011 | CA2467723C Method for treating cervical cancer |
| 09/27/2011 | CA2463865C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2463835C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2462337C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2453486C The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 09/27/2011 | CA2447276C Non-human animal model of oligodendrocyte developmental disorder |
| 09/27/2011 | CA2405811C Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 09/27/2011 | CA2213331C Chemokine receptors 88-2b [ckr-3] and 88c and their antibodies |
| 09/22/2011 | WO2011116123A1 Tafamidis for the treatment of ophthalmic diseases |
| 09/22/2011 | WO2011115271A1 Tumor angiogenesis inhibitor |
| 09/22/2011 | WO2011115268A1 Tumor angiogenesis inhibitor |
| 09/22/2011 | WO2011115225A1 Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| 09/22/2011 | WO2011115106A1 Pharmaceutical for pseudo-exercise therapy |
| 09/22/2011 | WO2011115062A1 Adjuvant having anti-tumor effect |
| 09/22/2011 | WO2011113904A1 Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| 09/22/2011 | WO2011113600A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/22/2011 | WO2010136168A8 Continuous administration of cilengitide in cancer treatments |
| 09/22/2011 | US20110230571 Diagnostic and therapeutic protocols |
| 09/22/2011 | US20110230550 Compounds, compositions and methods |
| 09/22/2011 | US20110230512 Pharmaceutical Composition |
| 09/22/2011 | US20110230448 Treatment and/or Prevention of Non-Viral Epithelial Damage |
| 09/22/2011 | US20110230446 Cathepsin cysteine protease inhibitors |
| 09/22/2011 | US20110230409 GLP-I Agonist And Cardiovascular Complications |
| 09/22/2011 | US20110229907 Use of cardiac hormones to assess risk of cardiovascular complication from volume overload |
| 09/22/2011 | US20110229585 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 09/22/2011 | US20110229571 Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker |
| 09/22/2011 | US20110229482 Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood by preventing viral entry into a cell |
| 09/22/2011 | US20110229466 Vascular endothelial growth factor 2 |
| 09/22/2011 | US20110229434 Uses of mammalian cytokine; related reagents |
| 09/22/2011 | US20110229409 Linkable lewis x analogs |
| 09/22/2011 | DE102010011919A1 Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine |
| 09/22/2011 | CA2793023A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 09/21/2011 | EP2366706A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 09/21/2011 | EP2366407A1 External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic |
| 09/21/2011 | EP2366398A1 Cancer therapy with a parvovirus combined with an HDAC inhibitor |
| 09/21/2011 | EP2365813A2 Methods of reducing the risk of cardiovascular disease in postmenopausal women |
| 09/21/2011 | EP2365808A1 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| 09/21/2011 | EP2365807A1 Oral composition |
| 09/21/2011 | EP1872796B1 Transdermal preparation for external use containing nonsteroidal antiinflammatory/analgesic agent |
| 09/21/2011 | EP1846035B1 Combination therapy |
| 09/21/2011 | EP1519956B1 Epha2 monoclonal antibodies and methods of use thereof |
| 09/21/2011 | EP1505963B9 Hepatitis c virus inhibitors |
| 09/21/2011 | EP1385993B8 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 09/21/2011 | EP1334178B1 Slo2 and slo4, novel potassium channel proteins from human brain |
| 09/21/2011 | EP1068357B1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 09/21/2011 | CN1711095B Composition for restoring damaged skin |
| 09/21/2011 | CN1468089B Microparticles for delivery of the heterologous nucleic acids |
| 09/21/2011 | CN102196820A S1P receptor agonists for the treatement of cerebral malaria |
| 09/21/2011 | CN102196819A Composition for local anesthesia |
| 09/21/2011 | CN102196808A S1P lyase inhibitors for the treatment of cerebral malaria |
| 09/21/2011 | CN102188709A Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors |
| 09/21/2011 | CN102188708A Compositions comprising nebivolol |
| 09/21/2011 | CN102188707A Application of IL-17 inhibitor in preparing medicament for treating influenza |
| 09/21/2011 | CN102188706A Fluvastatin tablet containing antiflatulent agent |
| 09/21/2011 | CN102188705A Medicament composition containing bis cyclooctane derivatives |
| 09/21/2011 | CN102188379A Preparation method of drug-carrying liposome |
| 09/21/2011 | CN102188373A Supersaturated self-microemulsified administration system for insoluble anti-tumor drugs, and preparation method thereof |
| 09/21/2011 | CN102188372A Medicinal transparent nano dispersant and preparation method thereof |
| 09/21/2011 | CN102188364A Preparation method of drug-carrying lipoid particles |
| 09/21/2011 | CN101721366B Components and preparation method of beta-lactam injection |
| 09/21/2011 | CN101538236B Method for synthesizing lauroyl-prolyl amino acid methyl ester as novel transdermal enhancer and applications thereof |
| 09/21/2011 | CN101355969B Antiproliferative combination comprising CYC-682 and a cytotoxic agent |
| 09/21/2011 | CN101352412B Intestinal-lysis non-steroidal antipyretic-antalgic anti-inflammatory agent and preparation thereof |
| 09/21/2011 | CN101343250B Thrombopoietin mimetics |
| 09/21/2011 | CN101166534B Therapeutic agent for chronic obstructive pulmonary disease |
| 09/20/2011 | US8022095 Comprises sumatriptan and naproxen as non-steroidal antiinflammatory agents (NSAIDS) |
| 09/20/2011 | US8022037 Skin wound healing compositions and methods of use thereof |
| 09/20/2011 | US8021862 Process for preparing human G-CSF |
| 09/20/2011 | US8021853 Inhibition of the β3 subunit of L-type Ca2+ channels |
| 09/20/2011 | US8021693 Methods of organ regeneration using Hox11-expressing pluripotent cells |
| 09/20/2011 | US8021644 Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis |
| 09/20/2011 | CA2515484C Modulation of insulin like growth factor i receptor expression |
| 09/20/2011 | CA2510760C Stimulation of in vivo production of proteins with formulation comprising leucine |
| 09/20/2011 | CA2482637C New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
| 09/20/2011 | CA2478253C Composition for hard tissue augmentation |
| 09/20/2011 | CA2476859C Water-based delivery systems |
| 09/20/2011 | CA2467237C Method of preventing or treating benign gynaecological disorders |
| 09/20/2011 | CA2458210C Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar-activators |
| 09/20/2011 | CA2439415C Cathepsin cysteine protease inhibitors |
| 09/20/2011 | CA2418135C Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 09/20/2011 | CA2417904C Compounds acting as melanocortin receptor ligands |
| 09/20/2011 | CA2416519C Transportation of nucleic acid substances |
| 09/20/2011 | CA2395814C Glp-2 formulations comprising phosphate buffer, l-histidine and mannitol or sucrose |
| 09/20/2011 | CA2376485C Recombinant anti-cd40 antibody and uses thereof |
| 09/20/2011 | CA2367149C Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 09/20/2011 | CA2223573C Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device |
| 09/20/2011 | CA2115828C Calcium receptor active molecules |
| 09/15/2011 | WO2011111698A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |